Atopic Dermatitis

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the importance of monitoring skin reactions during therapy.

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth cohorts from the Environmental Influences on Child Health Outcomes Children’s Respiratory and Environmental Workgroup.

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.

Researchers found a causal association between insomnia and atopic dermatitis and identified several genetic variations contributing to the association.

A new analysis suggests artificial intelligence algorithms are able to accurately assess lesion severity in patients with atopic dermatitis.

The findings, which add to the limited data on the burden of atopic dermatitis on adolescent and pediatric patients, showed differences in what was most bothersome to the younger group of patients.

Two studies explored the quality-of-life impacts of lebrikizumab for atopic dermatitis, finding its benefits extend beyond physical symptom improvements.

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis.

Patients with atopic dermatitis, particularly males and those aged 40 to 59 years, have significantly higher rates of impaired mobility.

Parental e-cigarette use was associated with an increased risk of pediatric atopic dermatitis (AD) in a new study.

Atopic dermatitis (AD) in visible areas significantly impacts the romantic relationships, occupations, and sexual health of French female adult patients, according to a new study.

A US-based discrete choice experiment survey found that patients with atopic dermatitis (AD) prioritize treatments that effectively control itching.

Educational interventions for patients, including both in-person and online methods, significantly reduced atopic dermatitis (AD) severity.

Patients with atopic dermatitis (AD) may have an increased risk of headache disorder and migraines.

A meta-analysis found significant associations between maternal stress, anxiety, depression, and adverse life events during pregnancy with increased atopic dermatitis (AD) risk in offspring.

Children with atopic dermatitis (AD) face higher chances of learning and memory difficulties, particularly when they have neurodevelopmental comorbidities, like attention-deficit/hyperactivity disorder.

Amy S. Paller, MD, of Feinberg School of Medicine at Northwestern University, noted that safety is of paramount importance when choosing which systemic therapy to use to treat children with atopic dermatitis (AD).

Amy S. Paller, MD, chair of the department of dermatology at Feinberg School of Medicine at Northwestern University, discussed using systemic therapies to treat children with atopic dermatitis (AD).

A considerable number of patients with atopic dermatitis (AD) and limited health literacy, especially older individuals, experienced impaired health-related quality of life.

This study enhances current understandings of dupilumab use in patients with atopic dermatitis (AD) by showing its real-world effectiveness and safety.

Adult patients with moderate to severe atopic dermatitis (AD) had a 1-year and 1.5-year upadacitinib drug survival of 91.5% and 80.2%, respectively.

This systemic review determined telemedicine to be as effective as in-person appointments for the follow-up of patients with atopic dermatitis (AD).

Although injection site reactions were common occurrences in both the tralokinumab and dupilumab groups, tralokinumab caused ISRs more frequently.

Dupilumab and topical corticosteroids can be used to treat symptoms in children with atopic dermatitis (AD).

Global warming, wildfires, precipitation, floods, and storms impact patients with atopic dermatitis (AD).